Option Millionaires

[uranium-pinto-beans]

Kairos Pharma opens at $4, IPO priced at $4 per share
Kairos Pharma priced its initial public offering of 1.55M shares of common stock at a public offering price of $4.00 per share. The company's common stock has been approved for listing on the NYSE American under the symbol "KAPA." The company intends to use the net proceeds from the offering to fund its Phase 1 trial in lung cancer and Phase 2 trial in prostate cancer for its lead product candidate ENV 105, designed to reverse resistance to standard of care drugs. The proceeds will also advance preclinical candidates, including KROS 101, a small molecule agonist for the GITR ligand, designed to promote T cell growth and cytotoxic function against cancer. Boustead Securities is acting as lead managing underwriter for the offering and EF Hutton is acting as co-managing underwriter for the offering.